Wegovy may have highest 'eye stroke' and sight loss risk among semaglutide GLP-1 agonists
Medical Xpress - medical research advances and health news [Uno…
March 10, 2026
Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of "eye stroke" (ischemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an analysis of unintended side effect reports published in the British Journal of Ophthalmology.
Discussion in the ATmosphere